Dna vaccine against amyloid-beta and tau

ABSTRACT

An object of the present invention is to provide a vaccine that can simultaneously reduce Aβ deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA encoding amyloid-β, DNA encoding an immunoglobulin Fc sequence, and DNA encoding tau.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of copending application Ser. No.15/578,123, filed on Nov. 29, 2017, which is a 35 U.S.C. 371 NationalStage of PCT International Application No. PCT/JP2016/081038 on Oct. 20,2016, which claims the benefit under 35 U.S.C. § 119(a) to PatentApplication No. 2015-207888, filed in Japan on Oct. 22, 2015, all ofwhich are hereby expressly incorporated by reference into the presentapplication.

TECHNICAL FIELD

The present invention relates to DNA vaccines against amyloid-β and tau.

BACKGROUND ART

Alzheimer's disease is a disease in which moderate to severe cerebralatrophy is grossly visible in the frontal association cortex, temporallobe, and hippocampal region, and is characterized by three majormicroscopic findings, i.e., senile plaques (amyloid-β (Aβ) deposition),neurofibrillary tangles (hyperphosphorylated tau deposition), andneuronal loss.

There are many reports that amyloid accumulation precedes tau depositionand neuronal changes, and amyloid accumulation has also been observed inautopsy brains of non-dementia elderly individuals and Down's syndromeindividuals. In recent years, the “amyloid hypothesis” has come to beaccepted, which assumes that amyloid deposition is positioned uppermostin this pathology, and the prevention of amyloid accumulation wouldallow subsequent events, such as intraneuronal tau accumulation andneuronal loss, to be prevented to a certain extent.

From pathological examination, however, it has been reported thatalthough anti-immunotherapy effectively reduces Aβ deposition, itseffect of reducing tau deposition is extremely weak (Non PatentLiterature 1: Boche, D. et al., Acta Neuropathol 120, 13-20).

At present, DNA vaccines against Aβ are known (Patent Literature 1: WO2010/110408); however, no DNA vaccine is known that can reduce Aβdeposition and tau deposition simultaneously by means of a singlemolecule.

PRIOR ART DOCUMENTS Patent Literature

-   Patent Literature 1: WO 2010/110408

Non Patent Literature

-   Non Patent Literature 1: Boche, D. et al., Acta Neuropathol 120,    13-20

SUMMARY OF INVENTION Problems to be Solved by the Invention

The present invention has been made in view of the aforementionedcircumstances, and the problem to be solved by the invention is toprovide a vaccine that can reduce Aβ deposition and tau deposition inthe brain simultaneously by means of a single molecule (singleconstruct).

Means for Solving the Problem

As a result of extensive research to solve the aforementioned problem,the present inventors succeeded in reducing Aβ deposition and taudeposition in the brain simultaneously by means of a single molecule,through the use of a recombinant vector comprising DNA encodingamyloid-β, DNA encoding an immunoglobulin Fc sequence, and DNA encodingtau, thereby completing the present invention.

In summary, the present invention is as set forth below.

(1) A recombinant vector comprising DNA encoding amyloid-β, DNA encodingan immunoglobulin Fc sequence, and DNA encoding tau.

(2) The vector according to (1) above, wherein the DNA encodingamyloid-β is DNA encoding repeats of amyloid-β sequence.

(3) The vector according to (1) or (2) above, wherein the DNA encodingtau is DNA encoding repeats of tau sequence.

(4) The vector according to any of (1) to (3) above, wherein theamyloid-β is Aβ1-42.

(5) A DNA vaccine for prevention or treatment of Alzheimer's disease,comprising the recombinant vector according to any of (1) to (4) above.

(6) A DNA vaccine for reducing brain Aβ and brain tau, comprising therecombinant vector according to any of (1) to (4) above.

(7) An inducer of anti-Aβ antibody and anti-tau antibody, comprising therecombinant vector according to any of (1) to (4) above.

(8) A polypeptide comprising amino acid sequences of amyloid-β, animmunoglobulin Fc sequence, and tau.

(9) The polypeptide according to (8) above, wherein the amyloid-βconsists of repeats of amyloid-β sequence.

(10) The polypeptide according to (8) or (9) above, wherein the tauconsists of repeats of tau sequence.

(11) The polypeptide according to any of (8) to (10) above, wherein theamyloid-β is Aβ1-42.

(12) A polypeptide expressed from the recombinant vector according toany of (1) to (4) above.

(13) A vaccine for prevention or treatment of Alzheimer's disease,comprising the polypeptide according to any of (8) to (12) above.

(14) A vaccine for reducing brain Aβ and brain tau, comprising thepolypeptide according to any of (8) to (12) above.

(15) An inducer of anti-Aβ antibody and anti-tau antibody, comprisingthe polypeptide according to any of (8) to (12) above.

Advantageous Effects of Invention

According to the present invention, Aβ deposition and tau deposition inthe brain can be reduced simultaneously by means of a single molecule.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows a schematic diagram of the structure of YM7555.

FIG. 2 shows the results of Western blotting detection of proteinexpression by the recombinant vector of the present invention.

FIG. 3 shows a graph showing the results of ELISA measurement of proteinexpression by the recombinant vector of the present invention.

FIG. 4 shows the schedule of immunization with YM7555 and bloodcollection.

FIG. 5 shows the results of induction of anti-Aβ antibody and anti-tauantibody in Tg mice.

FIG. 6 shows the results of induction of anti-Aβ antibody and anti-tauantibody in wild-type mice.

FIG. 7 shows graphs showing the effects of reducing brain Aβ and braintau according to the present invention.

FIG. 8 shows a schematic diagram of the structure of YM7555P.

DESCRIPTION OF EMBODIMENTS

The present invention will be hereinafter described in detail. Thefollowing embodiments are illustrative of the present invention, and arenot intended to limit the present invention. The present invention canbe carried out in various modes, without departing from the gist of theinvention.

1. Summary

At present, a construct comprising DNA encoding Aβ and a DNA vaccinecomprising such a construct are known (Patent Literature 1: WO2010/110408); however, a DNA vaccine that comprises both DNA encoding Aβand DNA encoding tau, in particular, a DNA vaccine that comprises DNAsencoding repeats of Aβ sequence and repeats of tau sequence, is unknown.One reason for this is that a skilled artisan predicts the possibilitythat if repeats of Aβ sequence and repeats of tau sequence werecombined, the respective sequences would conformationally interfere witheach other in the expressed polypeptide, leading to a failure to induceantibodies against Aβ or tau. Even if the skilled artisan attempts toprepare a construct comprising both DNA encoding Aβ and DNA encodingtau, the preparation of such a construct is technically difficult, whichis considered to be one reason why such a construct has never beenprepared in the past. Specifically, because each of the DNA encoding Aβand the DNA encoding tau has high hydrophobicity, and the DNA encodingrepeats of Aβ sequence and the DNA encoding repeats of tau sequencecomprise the repeats, these DNAs are likely to form a conformation dueto self-ligation when ligated using a generally known cloning method,and their ligation to a vector or the ligation reaction between theconstructs is unlikely to proceed. Thus, it has been technicallydifficult for the skilled artisan to prepare a construct comprising boththe DNA encoding Aβ and the DNA encoding tau, by using a general method.

Even if such a construct can be prepared, it has been extremelydifficult to prepare a DNA vaccine that can actually express in vivo apolypeptide comprising Aβ and tau as a single molecule, whichpolypeptide stimulates the immune system to induce the production ofantibodies against Aβ, tau, and their related substances, whichantibodies, in turn, can reduce Aβ and tau in the brain simultaneously.

Even if a skilled artisan considers in vivo expression of Aβ and tau,the skilled artisan would generally conceive of combined administrationof two types of molecules, i.e., a recombinant vector comprising DNAencoding Aβ and a recombinant vector comprising DNA encoding tau.

In contrast, the present inventors conducted extensive research based onthe idea that a DNA vaccine that can reduce Aβ deposition and taudeposition in the brain simultaneously by means of a single moleculewould be useful for treatment or prevention of Alzheimer's disease. As aresult, the present inventors succeeded in reducing Aβ deposition andtau deposition in the brain simultaneously by means of a singlemolecule, through the use of a recombinant vector comprising DNAencoding Aβ, DNA encoding an immunoglobulin Fc sequence, and DNAencoding tau, as a DNA vaccine, by employing the unique techniquesdescribed in the Examples of the present specification, therebycompleting the present invention.

In particular, the recombinant vector of the present invention, byvirtue of a synergistic effect of its components, can reducephosphorylated tau that is strongly neurotoxic in vivo, and thus, isextremely effective for treating or preventing Alzheimer's disease.

The term “simultaneously” as used herein is not necessarily intended tomean simultaneously in time, but also mean both at the same site (cellpopulation).

2. Recombinant Vector and Polypeptide

(1) Amyloid-β (Aβ)

Amyloid-β (Aβ) is a polypeptide consisting of 40-43 amino acids cleavedfrom the precursor protein (APP: amyloid-β protein precursor) by theaction of β- and γ-secretases.

The term “Aβ” as used herein refers to a polypeptide comprising 15 ormore contiguous amino acids, preferably 20 or more contiguous aminoacids, and more preferably refers to a polypeptide having an amino acidsequence consisting of amino acids 1-42 at the N-terminus of Aβ(Aβ1-42),in the native Aβ amino acid sequence.

Nucleotide sequences of DNAs encoding Aβ are available from givendatabases. For example, the nucleotide sequence as set forth in Genbankaccession no. NC_000021.7 can be used as a nucleotide sequence of DNAencoding human Aβ, and the nucleotide sequence as set forth in accessionno. NC_000082.5 can be used as a nucleotide sequence of DNA encodingmouse Aβ.

In the present invention, DNAs comprising nucleotide sequences ofvarious regions of Aβ can be prepared by performing PCR using DNAencoding Aβ as a template, and using primers for amplifying desiredregions. Examples of such DNAs include DNA encoding a polypeptide havingan amino acid sequence consisting of 43 amino acids cleaved byγ-secretase (designated as “Aβ1-43”); DNA encoding a polypeptide havingan amino acid sequence consisting of amino acids 1-20 at the N-terminusof Aβ (designated as “Aβ1-20”); DNA encoding a polypeptide having anamino acid sequence consisting of amino acids 1-40 at the N-terminus ofAβ (designated as “Aβ1-40”); and DNA encoding a polypeptide having anamino acid sequence consisting of amino acids 1-42 at the N-terminus ofAβ (designated as “Aβ1-42”). Preferred is the DNA encoding Aβ1-42.

In the present invention, examples of Aβ used in the polypeptidecomprising amino acid sequences of amyloid-β (Aβ), an immunoglobulin Fcsequence, and tau (hereinafter also referred to as the “polypeptide ofthe present invention”) include Aβ1-43, Aβ1-20, Aβ1-40, and Aβ1-42, withAβ1-42 being preferred.

The amino acid sequences of human Aβ1-43, Aβ1-20, Aβ1-40, and Aβ1-42 areshown in SEQ ID NOS: 2, 4, 6, and 8, respectively, and the amino acidsequences of mouse Aβ1-43, Aβ1-20, Aβ1-40, and Aβ1-42 are shown in SEQID NOS: 10, 12, 14, and 16, respectively. The nucleotide sequences ofDNAs encoding human Aβ1-43, Aβ1-20, Aβ1-40, and Aβ1-42 are shown in SEQID NOS: 1, 3, 5, and 7, respectively, and the nucleotide sequences ofDNAs encoding mouse Aβ1-43, Aβ1-20, Aβ1-40, and Aβ1-42 are shown in SEQID NOS: 9, 11, 13, and 15, respectively.

The DNA encoding human or mouse Aβ1-20, Aβ1-40, or Aβ1-42 can beprepared from the DNA encoding human or mouse Aβ1-43 by using PCR.

In addition to the DNAs encoding human or mouse Aβ1-43, Aβ1-20, Aβ1-40,and Aβ1-42 described above, the following DNAs can be used in therecombinant vector of the present invention:

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 1, and encoding a protein having human Aβ activity;

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 3, and encoding a protein having human Aβ activity;

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 5, and encoding a protein having human Aβ activity;

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 7, and encoding a protein having human Aβ activity;

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 9, and encoding a protein having mouse Aβ activity;

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 11, and encoding a protein having mouse Aβ activity;

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 13, and encoding a protein having mouse Aβ activity; and

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 15, and encoding a protein having mouse Aβ activity.

Each of human Aβ1-43, human Aβ1-20, human Aβ1-40, human Aβ1-42, mouseAβ1-43, mouse Aβ1-20, mouse Aβ1-40, and mouse Aβ1-42 has its own Aβactivity. Therefore, for example, in the case of a protein expressedfrom the DNA hybridizing under stringent conditions to DNA consisting ofa nucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 1, and encoding a protein having human Aβ activity, it issufficient for this protein to have Aβ activity equivalent to that ofhuman Aβ1-43. The same also applies to proteins expressed from DNAshybridizing under stringent conditions to DNAs consisting of nucleotidesequences complementary to the nucleotide sequences shown in other SEQID NOS, and encoding proteins having Aβ activity.

The term “stringent conditions” as used herein may refer to any oflow-stringency conditions, moderate-stringency conditions, andhigh-stringency conditions. The “low-stringency conditions” refers to,for example, conditions of 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50%formamide, and 32° C. The “moderate-stringency conditions” refers to,for example, conditions of 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50%formamide, and 42° C. The “high-stringency conditions” refers to, forexample, conditions of 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50%formamide, and 50° C. Under these conditions, it is expected that DNAhaving a higher homology will be efficiently obtained at a highertemperature. A plurality of factors such as temperature, probeconcentration, probe length, ionic strength, time, and saltconcentration are considered to affect the stringency of hybridization,and a skilled artisan can achieve the same stringency by selecting thesefactors as appropriate. For detailed hybridization procedures, referencemay be made to “Molecular Cloning, A Laboratory Manual (4th edition)”(Cold Spring Harbor Laboratory Press (2012)) and the like.

As the DNA encoding Aβ in the recombinant vector of the presentinvention, DNA having 50% or more, 60% or more, 70% or more, 80% ormore, 90% or more, 95% or more, 98% or more, or 99% or more homology(identity) to the nucleotide sequence shown in SEQ ID NO: 1, 3, 5, or 7,and encoding a protein having human Aβ activity, can be used. Moreover,DNA having 50% or more, 60% or more, 70% or more, 80% or more, 90% ormore, 95% or more, 98% or more, or 99% or more homology to thenucleotide sequence shown in SEQ ID NO: 9, 11, 13, or 15, and encoding aprotein having mouse Aβ activity, can also be used.

As Aβ in the polypeptide of the present invention, a polypeptide having70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% ormore, or 99% or more homology (identity) to the amino acid sequenceshown in SEQ ID NO: 2, 4, 6, 8, or 35, and having human Aβ activity, canbe used. Preferred as such Aβ is a polypeptide having 85% or morehomology to the amino acid sequence shown in SEQ ID NO: 8 or 35 andhaving human Aβ activity, and more preferred is a polypeptide having 90%or more homology to the amino acid sequence shown in SEQ ID NO: 8 or 35and having human Aβ activity. Furthermore, as Aβ in the polypeptide ofthe present invention, a polypeptide having 70% or more, 80% or more,90% or more, 95% or more, 98% or more, or 99% or more homology to theamino acid sequence shown in SEQ ID NO: 10, 12, 14, or 16, and havingmouse Aβ activity, can be used. Preferred as such Aβ is a polypeptidehaving 85% or more homology to the amino acid sequence shown in SEQ IDNO: 16 and having mouse Aβ activity, and more preferred is a polypeptidehaving 90% or more homology to the amino acid sequence shown in SEQ IDNO: 16 and having mouse Aβ activity.

In the polypeptide of the present invention, Aβ includes, in addition tothe polypeptide consisting of the amino acid sequence shown in SEQ IDNO: 2, 4, 6, 8, or 35, a polypeptide consisting of an amino acidsequence mutated by deletion, substitution, or addition, or acombination thereof, of one or more amino acids in the amino acidsequence shown in SEQ ID NO: 2, 4, 6, 8, or 35, and having human Aβactivity.

Examples of the above-described amino acid sequence mutated by deletion,substitution, or addition, or a combination thereof, of one or moreamino acids in the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8,or 35 include the following:

(i) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8,or 35 have been deleted;

(ii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8,or 35 have been substituted with other amino acids;

(iii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids have been added to the amino acid sequence shown in SEQ IDNO: 2, 4, 6, 8, or 35; and

(iv) an amino acid sequence mutated by a combination of (i) to (iii)above.

In the polypeptide of the present invention, Aβ includes, in addition tothe polypeptide consisting of the amino acid sequence shown in SEQ IDNO: 10, 12, 14, or 16, a polypeptide consisting of an amino acidsequence mutated by deletion, substitution, or addition, or acombination thereof, of one or more amino acids in the amino acidsequence shown in SEQ ID NO: 10, 12, 14, or 16, and having mouse Aβactivity.

Examples of the above-described amino acid sequence mutated by deletion,substitution, or addition, or a combination thereof, of one or moreamino acids in the amino acid sequence shown in SEQ ID NO: 10, 12, 14,or 16 include the following:

(i) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 10, 12, 14,or 16 have been deleted;

(ii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 10, 12, 14,or 16 have been substituted with other amino acids;

(iii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids have been added to the amino acid sequence shown in SEQ IDNO: 10, 12, 14, or 16; and

(iv) an amino acid sequence mutated by a combination of (i) to (iii)above.

The term “Aβ activity” as used herein is intended to mean the activityof Aβ to be produced, accumulate, and/or aggregate in the brain of asubject (such as a human or a mouse) to form Aβ deposition (senileplaques). The Aβ activity can be measured by an immunological techniquesuch as immunohistological staining or ELISA. With immunohistologicalstaining and the like, the Aβ activity can be measured by expressing theprotein to be evaluated in the brain of a test animal (such as a mouse),performing immunostaining using anti-Aβ antibody on tissue sections inwhich the protein has been expressed, and detecting Aβ production,accumulation, aggregation, and/or deposition and the like.

The phrase “having Aβ activity” as used herein is intended to meanhaving an activity of 10% or more, 20% or more, 30% or more, 40% ormore, 50% or more, 60% or more, 70% or more, 80% or more, and preferably90% or more, compared to the Aβ activity taken as 100% of a polypeptidehaving the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8, or 35, orSEQ ID NO: 10, 12, 14, or 16.

For the preparation of polypeptides having the above-describedmutations, mutations into polynucleotides can be introduced using amutagenesis kit that utilizes a site-directed mutagenesis method such asthe Kunkel method or Gapped duplex method, for example, QuikChange™Site-Directed Mutagenesis Kit (Stratagene), GeneTailor™ Site-DirectedMutagenesis System (Invitrogen), or TaKaRa Site-Directed MutagenesisSystem (Mutan-K, Mutan-Super Express Km, and the like; Takara Bio).Furthermore, methods such as site-directed mutagenesis methods asdescribed in the following literatures can be used: “Molecular Cloning,A Laboratory Manual (4th edition)” (Cold Spring Harbor Laboratory Press(2012)); “Current Protocols in Molecular Biology” (John Wiley & Sons(1987-1997)); Kunkel (1985) Proc. Natl. Acad. Sci. USA 82: 488-92;Kramer and Fritz (1987) Method. Enzymol. 154: 350-67; Kunkel (1988)Method. Enzymol. 85: 2763-6; and the like.

In the present invention, the DNA encoding Aβ may be DNA encodingrepeats of Aβ sequence. A vector comprising the DNA encoding repeats ofAβ sequence can express a plurality of Aβ or a polypeptide comprisingthe plurality of A. Furthermore, in the polypeptide of the presentinvention, Aβ may consist of repeats of Aβ sequence. The plurality of Aβor the polypeptide comprising the plurality of Aβ forms an Aβ oligomerextracellularly. This oligomer stimulates the immune system to induceantibodies against the Aβ oligomer. This is expected to reduce the Aβoligomer, which is more neurotoxic than the Aβ monomers.

The present invention can exert an enhanced effect of reducing brain Aβ,by comprising repeats of Aβ sequence or DNA encoding the same. Thepresent invention can also induce antibodies against various molecules(such as pEAβ3-42, ABri, and ADan) having neurotoxicity and high amyloidaggregation propensity, by comprising repeats of Aβ sequence or DNAencoding the same.

The range of the number of repeats of Aβ sequence is not limited as longas Aβ forms a folded structure to achieve improved antigenicity over Aβmonomers; the number of repeats of Aβ sequence is preferably 2 to 4,more preferably 3 to 4, and still more preferably 4.

(2) Tau

The recombinant vector of the present invention comprises DNA encodingtau. The polypeptide of the present invention also comprises an aminoacid sequence of tau.

Tau is a protein with a molecular weight of about 50,000 that is presentin nerve axons or the like, and contributes to microtubular stability.

In the present invention, tau may be either human-derived tau (humantau) or mouse-derived tau (mouse tau), and is preferably human tau.There are six isoforms of tau (0N3R, 1N3R, 0N3R, 2N3R, 1N4R, and 2N4R);however, in the present invention, tau is not limited to any of theseisoforms.

Nucleotide sequences of DNAs encoding tau are available from givendatabases. Examples of the available nucleotide sequence of DNA encodinghuman tau include, but not limited to, the nucleotide sequence of theDNA encoding isoform 2N4R of tau (Genbank accession no. NM_005910.5).The nucleotide sequence of the DNA encoding human tau (2N4R,full-length) is shown in SEQ ID NO: 17. The amino acid sequence of humantau (2N4R, full-length) is shown in SEQ ID NO: 18.

In the present invention, DNAs comprising nucleotide sequences ofvarious regions of tau can be prepared by performing PCR using DNAencoding tau as a template, and using primers for amplifying desiredregions. Examples of such DNAs include DNA encoding a polypeptide(partial polypeptide) comprising/consisting of an amino acid sequenceconsisting of at least 6 or more, 8 or more, 10 or more, 20 or more, or30 or more contiguous amino acid residues in the full-length amino acidsequence of tau. Specific examples of the DNA encoding the partialpolypeptide include DNA encoding a polypeptide comprising an amino acidsequence consisting of amino acid residues 295 to 305 at the N-terminusof tau (designated as “tau295-305”); and DNA encoding a polypeptidehaving an amino acid sequence consisting of amino acid residues 379 to408 at the N-terminus of tau (designated as “tau379-408”).

The nucleotide sequences of the DNA encoding human tau295-305 and theDNA encoding human tau379-408 are shown in SEQ ID NOS: 19 and 21,respectively. The amino acid sequences of human tau295-305 and humantau379-408 are shown in SEQ ID NOS: 20 and 22, respectively.

In addition to the DNAs encoding human tau described above, thefollowing DNAs can be used as the DNA encoding tau in the presentinvention:

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 17, and encoding a protein having tau activity;

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 19, and encoding a protein having tau activity; and

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 21, and encoding a protein having tau activity.

Each of human tau, human tau295-305, and human tau379-408 has its owntau activity. Therefore, for example, in the case of a protein expressedfrom the DNA hybridizing under stringent conditions to DNA consisting ofa nucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 17, and encoding a protein having tau activity, it issufficient for this protein to have tau activity equivalent to that ofhuman tau. The same also applies to proteins expressed from DNAshybridizing under stringent conditions to DNAs consisting of nucleotidesequences complementary to the nucleotide sequences shown in other SEQID NOS, and encoding proteins having tau activity.

The term “stringent conditions” is as defined above.

As the DNA encoding tau in the recombinant vector of the presentinvention, DNA having 50% or more, 60% or more, 70% or more, 80% ormore, 90% or more, 95% or more, 98% or more, or 99% or more homology(identity) to the nucleotide sequence shown in SEQ ID NO: 17, 19, or 21,and encoding a protein having human tau activity, can be used.

As tau in the polypeptide of the present invention, a polypeptide having70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% ormore, or 99% or more homology (identity) to the amino acid sequenceshown in SEQ ID NO: 18, 20, 22, or 24, and having human tau activity,can be used. Preferred as such tau is a polypeptide having 85% or morehomology to the amino acid sequence shown in SEQ ID NO: 18, 20, or 22and having human tau activity, and more preferred is a polypeptidehaving 90% or more homology to the amino acid sequence shown in SEQ IDNO: 18, 20, 22, or 24 and having human tau activity.

In the polypeptide of the present invention, tau includes, in additionto the polypeptide consisting of the amino acid sequence shown in SEQ IDNO: 18, 20, 22, or 24, a polypeptide consisting of an amino acidsequence mutated by deletion, substitution, or addition, or acombination thereof, of one or more amino acids in the amino acidsequence shown in SEQ ID NO: 18, 20, 22, or 24, and having human tauactivity.

Examples of the above-described amino acid sequence mutated by deletion,substitution, or addition, or a combination thereof, of one or moreamino acids in the amino acid sequence shown in SEQ ID NO: 18, 20, 22,or 24 include the following:

(i) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 18, 20, 22,or 24 have been deleted;

(ii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 18, 20, 22,or 24 have been substituted with other amino acids;

(iii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids have been added to the amino acid sequence shown in SEQ IDNO: 18, 20, 22, or 24; and

(iv) an amino acid sequence mutated by a combination of (i) to (iii)above.

The term “tau activity” as used herein is intended to mean the activityof tau to be produced, accumulate, and/or aggregate in the brain of asubject (such as a human or a mouse). The tau activity can be measuredby an immunological technique such as immunohistological staining orELISA. With immunohistological staining, for example, the tau activitycan be measured by expressing the protein to be evaluated in the brainof a test animal (such as a mouse), performing immunostaining usinganti-tau antibody on tissue sections in which the protein has beenexpressed, and detecting tau production, accumulation, aggregation,and/or deposition and the like.

The phrase “having human tau activity” as used herein is intended tomean having an activity of 10% or more, 20% or more, 30% or more, 40% ormore, 50% or more, 60% or more, 70% or more, 80% or more, and preferably90% or more, compared to the human tau activity taken as 100% of apolypeptide having the amino acid sequence shown in SEQ ID NO: 18, 20,22, or 24.

The method for preparing polypeptides having such mutations is asdescribed above.

In the present invention, the DNA encoding tau may be DNA encodingrepeats of tau sequence. Furthermore, in the polypeptide of the presentinvention, tau may consist of repeats of tau sequence. A vectorcomprising the DNA encoding repeats of tau sequence can express aplurality of tau or a polypeptide comprising the plurality of tau.Examples of the DNA encoding repeats of tau sequence include DNAencoding repeats of human tau295-305 sequence or human tau379-408sequence. Examples of polypeptides comprising amino acid sequences ofrepeats of tau sequence include a polypeptide comprising an amino acidsequence of the repeats of human tau295-305 or human tau379-408.

The range of the number of repeats of tau sequence is not limited aslong as tau forms a folded structure to achieve improved antigenicityover tau; the number of repeats of tau sequence is preferably 2 to 4,more preferably 3 to 4, and still more preferably 4.

Phosphorylated tau molecules lose their microtubule-binding ability, andare bound together to form aggregates. The recombinant vector andpolypeptide of the present invention, by virtue of a synergistic effectof components thereof, can reduce phosphorylated tau that is stronglyneurotoxic in vivo, and thus, is extremely effective for treating orpreventing Alzheimer's disease.

(3) Immunoglobulin Fc (IgFc) Sequence

The recombinant vector of the present invention comprises DNA encodingan immunoglobulin Fc (IgFc) sequence. The polypeptide of the presentinvention also comprises an amino acid sequence of the IgFc sequence.Introduction of a gene encoding the IgFc sequence into the living bodycan promote intracellular transcription and translation of thepolypeptides comprising Aβ and tau, and can further promoteextracellular release of these polypeptides to more strongly stimulateimmune responses against Aβ and tau.

Examples of the IgFc sequence used in the present invention include ahuman IgFc sequence and a mouse IgFc sequence. The nucleotide sequenceas set forth in Genbank accession no. BC014258 can be used as anucleotide sequence of DNA encoding a human IgFc sequence, and thenucleotide sequence as set forth in accession no. XM_484178.3 can beused as a nucleotide sequence of DNA encoding a mouse IgFc sequence.

SEQ ID NOS of the nucleotide sequences of the DNAs encoding the humanand mouse IgFc sequences used in the present invention, as well as theamino acid sequences of these human and mouse IgFc sequences, are shownbelow:

The nucleotide sequence of the DNA encoding the human IgFc sequence: SEQID NO: 25

The amino acid sequence of the human IgFc sequence: SEQ ID NO: 26 Thenucleotide sequence of the DNA encoding the mouse IgFc sequence: SEQ IDNO: 27

The amino acid sequence of the mouse IgFc sequence: SEQ ID NO: 28

Each of the nucleotide sequences shown in SEQ ID NOS: 25 and 27 is anucleotide sequence into which mutations have been introduced tosubstitute cysteine residues in the original IgFc sequence with serineresidues. This is intended to avoid the formation of disulfide bonds.

The following DNAs can also be used as the DNAs encoding the human andmouse IgFc sequences used in the present invention:

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 25, and encoding a protein having human IgFc activity; and

DNA hybridizing under stringent conditions to DNA consisting of anucleotide sequence complementary to the nucleotide sequence shown inSEQ ID NO: 27, and encoding a protein having mouse IgFc activity.

The term “IgFc activity” as used herein is intended to mean the activitythat promotes intracellular production and extracellular release of thepolypeptide comprising the IgFc sequence. For example, the IgFc activityof a certain protein can be measured by expressing a fusion protein ofIgFc and a polypeptide of interest in cultured cells, and quantifying anincrease in the amount of the polypeptide present in the cultured cellsor culture supernatant. The polypeptide can be quantified using animmunological technique such as ELISA or EIA.

As the DNA encoding the IgFc sequence in the recombinant vector of thepresent invention, DNA having 50% or more, 60% or more, 70% or more, 80%or more, 90% or more, 95% or more, 98% or more, or 99% or more homologyto the nucleotide sequence shown in SEQ ID NO: 25, and encoding aprotein having human IgFc activity, can be used. Moreover, DNA having50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% ormore, 98% or more, or 99% or more homology to the nucleotide sequenceshown in SEQ ID NO: 27, and encoding a protein having mouse IgFcactivity, can also be used.

The IgFc activity is as described above.

As the IgFc sequence in the polypeptide of the present invention, apolypeptide having 70% or more, 80% or more, 85% or more, 90% or more,95% or more, 98% or more, or 99% or more homology (identity) to theamino acid sequence shown in SEQ ID NO: 26, and having human IgFcactivity, can be used. Preferred as such an IgFc sequence is apolypeptide having 85% or more homology to the amino acid sequence shownin SEQ ID NO: 26 and having human IgFc activity, and more preferred is apolypeptide having 90% or more homology to the amino acid sequence shownin SEQ ID NO: 26 and having human IgFc activity. Furthermore, as theIgFc sequence in the polypeptide of the present invention, a polypeptidehaving 70% or more, 80% or more, 90% or more, 95% or more, 98% or more,or 99% or more homology to the amino acid sequence shown in SEQ ID NO:28, and having mouse IgFc activity, can be used. Preferred as such anIgFc sequence is a polypeptide having 85% or more homology to the aminoacid sequence shown in SEQ ID NO: 28 and having mouse IgFc activity, andmore preferred is a polypeptide having 90% or more homology to the aminoacid sequence shown in SEQ ID NO: 28 and having mouse IgFc activity.

In the polypeptide of the present invention, the IgFc sequence includes,in addition to the polypeptide consisting of the amino acid sequenceshown in SEQ ID NO: 26, a polypeptide consisting of an amino acidsequence mutated by deletion, substitution, or addition, or acombination thereof, of one or more amino acids in the amino acidsequence shown in SEQ ID NO: 26, and having human IgFc activity.

Examples of the above-described amino acid sequence mutated by deletion,substitution, or addition, or a combination thereof, of one or moreamino acids in the amino acid sequence shown in SEQ ID NO: 26 includethe following:

(i) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 26 have beendeleted;

(ii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 26 have beensubstituted with other amino acids;

(iii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids have been added to the amino acid sequence shown in SEQ IDNO: 26; and

(iv) an amino acid sequence mutated by a combination of (i) to (iii)above.

In the polypeptide of the present invention, the IgFc sequence includes,in addition to the polypeptide consisting of the amino acid sequenceshown in SEQ ID NO: 28, a polypeptide consisting of an amino acidsequence mutated by deletion, substitution, or addition, or acombination thereof, of one or more amino acids in the amino acidsequence shown in SEQ ID NO: 28, and having mouse IgFc activity.

Examples of the above-described amino acid sequence mutated by deletion,substitution, or addition, or a combination thereof, of one or moreamino acids in the amino acid sequence shown in SEQ ID NO: 28 includethe following:

(i) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 28 have beendeleted;

(ii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 28 have beensubstituted with other amino acids;

(iii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids have been added to the amino acid sequence shown in SEQ IDNO: 28; and

(iv) an amino acid sequence mutated by a combination of (i) to (iii)above.

In another aspect, the recombinant vector of the present inventioncomprises a polynucleotide comprising DNA encoding amyloid-β, DNAencoding an immunoglobulin Fc sequence, and DNA encoding tau.

Examples of such polynucleotides include, although not limited to, apolynucleotide consisting of the nucleotide sequence shown in SEQ ID NO:30 (DNA encoding YM7555P). In the recombinant vector of the presentinvention, in addition to the polynucleotide consisting of thenucleotide sequence shown in SEQ ID NO: 30, the followingpolynucleotides can be used:

a polynucleotide hybridizing under stringent conditions to apolynucleotide consisting of a nucleotide sequence complementary to thenucleotide sequence shown in SEQ ID NO: 30, and encoding a polypeptidehaving an activity to induce anti-Aβ antibody and/or anti-tau antibody;and

a polynucleotide having 50% or more, 60% or more, 70% or more, 80% ormore, 90% or more, 95% or more, 98% or more, or 99% or more (preferably90% or more) homology (identity) to the nucleotide sequence shown in SEQID NO: 30, and encoding a polypeptide having an activity to induceanti-Aβ antibody and/or anti-tau antibody.

The phrase “activity to induce anti-Aβ antibody and/or anti-tauantibody” as used herein is intended to mean an activity to induceanti-Aβ antibody and/or anti-tau antibody in vivo in a mammal serving asa subject (such as a mouse or a human). This activity can be measured byan immunological technique such as immunohistological staining, Westernblotting, or ELISA. For example, this activity can be measured byadministering the polypeptide of the present invention or therecombinant vector expressing the same to a mammal, collecting bloodfrom the mammal, and measuring the antibody titer of the anti-Aβantibody and/or the anti-tau antibody in the blood using ELISA.

The phrase “having an activity to induce anti-Aβ antibody and/oranti-tau antibody” is intended to mean having an activity of 10% ormore, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more,70% or more, 80% or more, and preferably 90% or more, compared to theactivity taken as 100% of the polypeptide having the amino acid sequenceshown in SEQ ID NO: 31.

The term “stringent conditions” is as defined above.

Examples of the polypeptide of the present invention include, althoughnot limited to, a polypeptide consisting of the amino acid sequenceshown in SEQ ID NO: 31 (YM7555P). In addition to the polypeptideconsisting of the amino acid sequence shown in SEQ ID NO: 31, thefollowing polypeptides can be used as the polypeptide of the presentinvention:

a polypeptide having 70% or more, 80% or more, 85% or more, 90% or more,95% or more, 98% or more, or 99% or more (preferably 90% or more)homology (identity) to the amino acid sequence shown in SEQ ID NO: 31,and having an activity to induce anti-Aβ antibody and/or anti-tauantibody; and

a polypeptide consisting of an amino acid sequence mutated by deletion,substitution, or addition, or a combination thereof, of one or moreamino acids in the amino acid sequence shown in SEQ ID NO: 31, andhaving an activity to induce anti-Aβ antibody and/or anti-tau antibody.

Examples of the above-described amino acid sequence mutated by deletion,substitution, or addition, or a combination thereof, of one or moreamino acids in the amino acid sequence shown in SEQ ID NO: 31 includethe following:

(i) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 31 have beendeleted;

(ii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids in the amino acid sequence shown in SEQ ID NO: 31 have beensubstituted with other amino acids;

(iii) an amino acid sequence in which 1 to 10 (for example, 1 to 5,preferably 1 to 3, more preferably 1 or 2, and still more preferably 1)amino acids have been added to the amino acid sequence shown in SEQ IDNO: 31; and

(iv) an amino acid sequence mutated by a combination of (i) to (iii)above.

(4) Preparation of Recombinant Vector

The recombinant vector of the present invention comprises DNA encodingAβ, DNA encoding an immunoglobulin Fc (IgFc) sequence, and DNA encodingtau.

The DNA encoding Aβ, tau, or the IgFc sequence may be derived from thesame animal species as or different animal species from the animalserving as a subject that will receive the administration of the DNAvaccine; however, it is preferred to use DNA encoding Aβ, tau, or anIgFc sequence derived from the same animal species.

Each of the DNA encoding Aβ, the DNA encoding the IgFc sequence, and theDNA encoding tau has already been cloned. Thus, the DNAs comprised inthe vector of the present invention can be obtained using a generalgenetic engineering technique. For example, a nucleic acid synthesismethod using a DNA synthesizer, which is commonly used as a geneticengineering technique, can be used. Moreover, a PCR method that involvesisolating or synthesizing DNA sequences for use as templates, designingprimers specific for each of the DNAs, and amplifying the gene sequenceusing a PCR system, or a gene amplification method using a cloningvector, can be used. Furthermore, each of the DNAs can be obtained froma cDNA library or genomic library by performing a known hybridizationmethod such as colony hybridization, plaque hybridization, or Southernblotting, using, as a probe, DNA consisting of the nucleotide sequenceshown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 18, 19, 21, 25, or27, or a fragment thereof. The above-described methods can be readilyperformed by a skilled artisan in accordance with “Molecular Cloning, ALaboratory Manual (4th edition)” (Cold Spring Harbor Laboratory Press(2012)) and the like. A known method can be used to purify the resultingPCR products.

A general genetic engineering technique can be adopted to prepare therecombinant vector. For example, samples of the DNAs of interestencoding Aβ, tau, and the IgFc sequence are prepared by PCR and thelike. PCR can be performed by a general method using KOD polymerase oranother DNA polymerase a. The amplified fragments of interest aredigested with restriction enzymes, and then inserted into restrictionenzyme sites or a multi-cloning site in a plasmid vector such as pCR(registered trademark)-Blunt II-TOPO (registered trademark) vector(Invitrogen). The resulting PCR products are confirmed for theirnucleotide sequences with a sequencer to select a plasmid comprising theproper sequence. It is preferred that such a DNA sample can be confirmedas an electrophoretically single plasmid.

As a promoter comprised in the recombinant vector of the presentinvention, actin promoter, EF1 promoter, CMV promoter, CAG promoter orthe like can be used. These promoters may each be ligated to anappropriate plasmid.

The term “stringent conditions” is as defined above. The phrase “havingpromoter activity” is intended to mean having the transcriptionalactivity of a gene encoding a structural protein or a non-structuralprotein.

In the vector of the present invention, the above-described Aβ, tau, andIgFc sequence are comprised in operable form to allow their expression.Specifically, the transgenes (DNAs) are inserted into the vector in amanner that allows expression of the transgenes under the control ofappropriate regulatory elements. The DNA encoding Aβ, the DNA encodingthe IgFc sequence, and the DNA encoding tau may be individually insertedinto different sites in the same vector, or may be inserted contiguouslyin tandem. The term “regulatory elements” as used herein refers to, forexample, promoters, enhancers, and transcription terminators.

The vector of the present invention may carry an additional foreign geneat a position different from the regions into which the DNA encoding Aβ,the DNA encoding the IgFc sequence, and the DNA encoding tau have beeninserted. Such a foreign gene may be, for example, although notparticularly limited to, a marker gene for vector monitoring, aregulatory gene for the immune system such as a cytokine or hormone, ora signal sequence (leader sequence).

Examples of the recombinant vector of the present invention include thefollowing:

(i) pVAX1 comprising DNA encoding Aβ1-42, DNA encoding the IgFcsequence, and DNA encoding tau, downstream of the CMV promoter;

(ii) pVAX1 comprising DNA encoding repeats of Aβ1-42 sequence, DNAencoding the IgFc sequence, and DNA encoding tau, downstream of the CMVpromoter;

(iii) pVAX1 comprising DNA encoding Aβ1-42, DNA encoding the IgFcsequence, and DNA encoding repeats of tau sequence, downstream of theCMV promoter; and

(iv) pVAX1 comprising DNA encoding repeats of Aβ1-42 sequence, DNAencoding the IgFc sequence, and DNA encoding repeats of tau sequence,downstream of the CMV promoter.

Examples of “tau” used herein include human tau (full-length), humantau295-305, and human tau379-408, with human tau379-408 being preferred.

Preferably, pVAX1 comprising DNA encoding Aβ1-42, DNA encoding the IgFcsequence, and DNA encoding tau downstream of the CMV promoter comprisesan Ig leader (IgL) sequence between the CMV promoter and the DNAencoding Aβ1-42, and comprises a spacer sequence (also referred to asthe “linker”) between the DNA encoding the IgFc sequence and the DNAencoding tau. More preferably, such pVAX1 comprises the CMV promoter,the Ig leader sequence, the DNA encoding Aβ1-42, the DNA encoding theIgFc sequence, the spacer sequence, and the DNA encoding tau in thisorder.

Preferably, pVAX comprising DNA encoding repeats of Aβ1-42 sequence, DNAencoding the IgFc sequence, and DNA encoding repeats of tau sequencedownstream of the CMV promoter comprises an Ig leader (IgL) sequencebetween the CMV promoter and the DNA encoding repeats of Aβ1-42sequence, and comprises spacer sequences between individual “DNAsencoding Aβ1-42” of the DNA encoding repeats of Aβ1-42 sequence, betweenthe DNA encoding the IgFc sequence and the DNA encoding repeats of tausequence, and between individual “DNAs encoding tau” of the DNA encodingrepeats of tau sequence. More preferably, such pVAX1 comprises the CMVpromoter, the Ig leader sequence, the DNA encoding repeats of Aβ1-42sequence, the DNA encoding the IgFc sequence, the spacer sequence, andthe DNA encoding repeats of tau sequence in this order (FIG. 1).

The above-described recombinant vectors can comprise DNAs of mouse orhuman origin. Vectors comprising DNAs of mouse origin can be used inpreclinical trials or reagents, while vectors comprising DNAs of humanorigin can be used in pharmaceutical compositions or reagents.

In accordance with the same technique as described above, a vector thatdoes not comprise the DNA encoding Aβ1-42 but comprises the Ig leader(IgL) sequence, the DNA encoding tau, and the DNA encoding the IgFcsequence can be prepared. Examples of such vectors include a vectorcomprising IgL-tau×1-huFc (the Ig leader (IgL) sequence, DNA encodingone tau sequence, and DNA encoding the IgFc sequence); and a vectorcomprising IgL-Tau×4-huFc (the Ig leader (IgL) sequence, DNA encodingfour repeats of tau sequence, and DNA encoding the IgFc sequence; alsodesignated herein as “tau×4-IgFc”).

(5) Preparation of Polypeptide

The polypeptide of the present invention comprises amino acid sequencesof amyloid-β, an immunoglobulin Fc sequence, and tau.

The polypeptide of the present invention can be prepared using a knowntechnique, and can be specifically produced as follows.

(i) Preparation of Expression Vector

The vector for expressing the polypeptide of the present invention isnot limited to particular vectors as long as host cells can carry thevector for expression, and examples thereof include plasmid DNAs andbacteriophages. Examples of plasmid DNAs include, although not limitedto, plasmid vectors such as pCR (registered trademark)-Blunt II-TOPO(registered trademark) vector (Invitrogen).

As the vector for expressing the polypeptide of the present invention,the recombinant vector prepared in accordance with “(4) Preparation ofRecombinant Vector” above can be used. Specifically, the polypeptide ofthe present invention may be a polypeptide expressed from therecombinant vector comprising DNA encoding amyloid-β, DNA encoding theimmunoglobulin Fc sequence, and DNA encoding tau.

(ii) Transformation

Examples of hosts for producing the polypeptide of the present inventioninclude, although not limited to, mammalian cells, bacteria such asBifidobacterium bifidum, lactobacilli, and E. coli, insect cells,yeasts, and molds.

The recombinant DNA can be introduced into a host using a known method.Examples of methods for introducing the above-described vector into ahost include the calcium phosphate method, the DEAE-dextran method,electroporation, and the cationic lipid method.

The introduction of DNA can be confirmed using selection marker genes(such as ampicillin resistance gene, neomycin resistance gene,hygromycin resistance gene, tetracycline resistance gene,chloramphenicol resistance gene, kanamycin resistant gene, zeocinresistance gene, and blasticidin resistance gene).

(iii) Production of Polypeptide

The polypeptide of the present invention can be obtained by culturingthe above-described transformant comprising the polynucleotide encodingthe polypeptide or a variant thereof, and collecting the polypeptidefrom the culture.

The term “culture” refers to any of culture supernatant, cultured cells,cultured bacteria, or cell or bacterial homogenates. The transformant ofthe present invention is cultured in accordance with a general methodused for culturing of a host.

For culturing of a recombinant transfected with an expression vectorcomprising an inducible transcription promoter as a promoter, an inducermay be added to the medium, as required. When IPTG is used as aninducer, IPTG is added in an amount of 0.1 to 1.0 mM. IPTG is added 2 to12 hours after the start of culture, and, after the addition, theculture is continued for additional 1 to 12 hours.

If the polypeptide of the present invention accumulates in the bacteriaor cells after the culture, the polypeptide of interest is collected byhomogenizing the bacteria or cells with a homogenizer and the like. Whenthe polypeptide of the present invention is produced outside thebacteria or cells, the culture is used as is, or the bacteria or cellsis removed by, for example, centrifugation. Then, the polypeptide iscollected from the culture using ammonium sulfate precipitationprocedures and the like, and then isolated and purified, as required,using any of various types of chromatography and the like.

As the cell extract, extracts from eukaryotic or prokaryotic cells canbe used, which include, for example, extracts of wheat germ, rabbitreticulocytes, mouse L-cells, HeLa cells, CHO cells, budding yeast, andE. coli. These cell extracts may be concentrated or not concentrated.

(iv) Peptide Synthesis

The polypeptide of the present invention can be obtained by chemicalsynthesis. Peptide synthesis can be performed by an existing method witha synthesizer. Alternatively, the polypeptide of the present inventioncan be obtained by requesting the peptide synthesis to and purchasingfrom a custom peptide synthesis service company.

3. Vaccines (DNA Vaccine Comprising Recombinant Vector and VaccineComprising Polypeptide) and Inducer of Anti-Aβ Antibody and Anti-TauAntibody

The present invention provides a DNA vaccine (pharmaceuticalcomposition) for prevention or treatment of Alzheimer's disease, whichcomprises the above-described recombinant vector. In another aspect, thepresent invention provides a DNA vaccine for reducing brain Aβ and braintau, which comprises the above-described vector.

Such a DNA vaccine is intended to induce antibodies against the proteinsof interest in a living body by: integrating DNAs encoding the proteinsof interest into a vector (a plasmid or virus); administering the vectorto the living body; and expressing the proteins of interest in theliving body in which the vector has been administered to stimulate theimmune system. The DNA vaccine remains in the body for a long time afterthe administration, and continues to slowly produce the encodedproteins. Thus, excessive immune responses can be avoided. The DNAvaccine can also be modified using a genetic engineering technique.

The present invention also provides a vaccine (pharmaceuticalcomposition) comprising the polypeptide comprising amino acid sequencesof amyloid-β, the immunoglobulin Fc sequence, and tau. In anotheraspect, the present invention provides a vaccine for reducing brain Aβand brain tau, which comprises the above-described polypeptide.

The term “treatment”, “treat”, or “treating” as used herein refers tocontacting (for example, administering) the vaccine of the presentinvention with a subject after the onset of a disease, therebyalleviating symptoms of the disease, compared to when the subject is notcontacted with the vaccine, and does not completely suppressing thesymptoms of the disease. The “onset of a disease” refers to themanifestation of symptoms of the disease in the body.

The term “prevention”, “prevent”, or “preventing” as used herein refersto contacting (for example, administering) the vaccine of the presentinvention with a subject before the onset of a disease, therebyalleviating symptoms of the disease after the onset of the disease,compared to when the subject is not contacted with the vaccine, and doesnot refer to completely suppressing the onset of the disease.

The term “reduction”, “reduce”, or “reducing” as used herein refers todecreasing the amount of Aβ and/or tau present in the brain, whichencompasses decreasing the amount of brain Aβ and/or brain tauaccumulated, aggregated, or deposited in the brain. Furthermore, the DNAvaccine of the present invention comprising the above-described vectorcan also be used as a vaccine for suppressing an increase in the amountof brain Aβ and/or brain tau.

In another aspect, the present invention provides an inducer of anti-Aβantibody and anti-tau antibody, which comprises the above-describedvector or polypeptide.

The presence of various subspecies of neurotoxic Aβ has been recentlyrevealed. Aβ oligomers, which are most intensively analyzed, can bedivided into those of low-molecular-weight type formed by aggregation of2, 3, or 4 molecules, and those of high-molecular-weight type formed byaggregation of 12 or more molecules. Moreover, strong neurotoxicity hasalso been observed in pEAβ3-42, which is N-terminally truncated andpyrrole-modified by post-translational modification (Saido et al.,Neurosci Lett, 215, 173-176, 1996; Schlenzig et al., Biochemistry, 48,7072-7078, 2009). Furthermore, some findings have been obtained whichsuggest that molecules such as ABri (Ghiso et al., Brain Pathol, 16,71-79, 2006) and ADan, which have high amyloid aggregation propensityalthough completely differing in amino acid sequence from Aβ, are alsoimplicated in the onset of Alzheimer's disease.

The recombinant vector and the polypeptide of the present invention canalso induce antibodies against various molecules (such as pEAβ3-42,ABri, and ADan) having neurotoxicity and high amyloid aggregationpropensity.

pEAβ3-42 is a molecule produced from Aβ1-42 by N-terminal truncationwith glutaminyl cyclase (QC) and post-translational modification(pyrrole modification). pEAβ3-42 is highly neurotoxic, and this moleculeitself has a high tendency to aggregate. pEAβ3-42 also acts to enhancethe aggregation propensity of unmodified Aβ, and is one of the majorfactors responsible for lesion formation in Alzheimer's disease.

ABri is a causative molecule for familial British dementia, while ADanis a causative molecule for familial Danish dementia. ABri and ADan aremolecules produced by being cleaved as long molecules from theirprecursor proteins, due to a gene mutation in the stop codon of eachprecursor protein. ABri and ADan have high amyloid aggregationpropensity (amyloid collectively refers to the phenomenon in which smallmolecules are aggregated and deposited), and are key molecules in thedisease progression. ABri and ADan are thus considered to play some rolein the lesion formation in Alzheimer's disease.

When the vector of the present invention is used as a DNA vaccine or aninducer of anti-Aβ antibody and anti-tau antibody, gene transfer can beaccomplished either by directly administering the vector to a targetsite of a subject, or by indirectly administering the vector byinfecting the vector into the subject-derived cells or other cells forgene transfer, and then injecting the infected cells into a target site.Likewise, when the polypeptide of the present invention is used as a DNAvaccine or an inducer of anti-Aβ antibody and anti-tau antibody, it canbe directly administered to a target site of a subject.

Furthermore, the vector or polypeptide of the present invention may beintroduced into phospholipid vesicles such as liposomes, foradministration of the vesicles. The vesicles carrying the vector orpolypeptide of the present invention may be introduced by lipofectioninto given cells. And then, the resulting cells may be administeredsystemically, for example, intravenously or intraarterially. Theresulting cells may be administered locally to the brain and the like.

Examples of lipids for forming liposome structures includephospholipids, cholesterols, and nitrogen-containing lipids.Phospholipids are generally suitable, which include naturalphospholipids such as phosphatidylcholine, phosphatidylserine,phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine,phosphatidic acid, cardiolipin, sphingomyelin, egg yolk lecithin,soybean lecithin, and lysolecithin, as well as hydrogenated productsthereof obtained in accordance with a standard method. Syntheticphospholipids can also be used, which include dicetyl phosphate,distearoylphosphatidylcholine, dipalmitoylphosphatidylcholine,dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylserine,eleostearoylphosphatidylcholine, andeleostearoylphosphatidylethanolamine.

Liposomes can be produced using any method that allows the liposomes tocarry the DNA or polypeptide, including, for example, conventionalmethods such as reverse phase evaporation, ether injection, andsurfactant-based techniques.

Lipids including these phospholipids can be used singly or incombinations of two or more. In this case, a lipid containing an atomicgroup having a cationic group in the molecule, such as ethanolamine orcholine, may be used to increase the binding rate of electricallynegative DNA. In addition to these major phospholipids for liposomeformation, other additives such as cholesterols, stearyl amine, andα-tocopherol, which are generally known as liposome-forming additives,can also be used. The liposomes thus obtained can further contain amembrane fusion promoter, such as polyethylene glycol, in order toenhance their uptake into cells in the affected area or target tissue.

The vaccine, the inducer of anti-Aβ antibody and anti-tau antibody, orthe like of the present invention can be formulated in accordance with aroutine method, and may comprise pharmaceutically acceptable carriers.Such carriers may be additives, including water, pharmaceuticallyacceptable organic solvents, collagen, polyvinyl alcohol,polyvinylpyrrolidone, carboxyvinyl polymers, carboxymethylcellulosesodium, sodium polyacrylate, sodium alginate, water-soluble dextran,carboxymethyl starch sodium, pectin, methylcellulose, ethylcellulose,xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycerine,glycerine, propylene glycol, petrolatum, paraffin, stearyl alcohol,stearic acid, human serum albumin, mannitol, sorbitol, lactose, andsurfactants acceptable as pharmaceutical additives.

The above-described additives can be selected singly or as anappropriate combination from among those listed above, according to thedosage form of the vaccine or the inducer of anti-Aβ antibody andanti-tau antibody of the present invention. For example, for use asinjectable formulations, the purified vector can be dissolved in asolvent (for example, physiological saline, buffer, or glucosesolution), and then supplemented with Tween 80, Tween 20, gelatin, humanserum albumin, or the like. Alternatively, the vaccine or the inducermay be lyophilized for use as dosage forms that are dissolved beforeuse. Examples of excipients for lyophilization include saccharides suchas mannitol, glucose, lactose, sucrose, and sorbitol; starches such asthose derived from corn, wheat, rice, potato, and other plants;celluloses such as methylcellulose, hydroxypropylmethylcellulose, andcarboxymethylcellulose sodium; gums such as gum arabic and gumtragacanth; gelatin; and collagen.

Examples of subjects to receive the administration of the vaccine, theinducer of anti-Aβ antibody and anti-tau antibody, or the like of thepresent invention include mammals, including, for example, humans; aswell as non-human primates such as monkeys; rodents such as mice andrats; and all other mammals such as rabbits, goats, sheep, pigs, cattle,and dogs; with humans being preferred. Animals (subjects) to receive theadministration are, for example, those suffering from Alzheimer'sdisease, those suspected to have Alzheimer's disease, those showingincreased Aβ deposition, those showing increased tau deposition, orthose showing neuronal loss. Subjects to receive the administration mayalso be subjects (patients) in need of treatment and/or prevention ofAlzheimer's disease, reduction in brain Aβ and brain tau, and/orinduction of anti-Aβ antibody and anti-tau antibody.

The dosage of the vaccine, the inducer of anti-Aβ antibody and anti-tauantibody, or the like of the present invention will vary depending onthe age, sex, symptoms, route of administration, frequency ofadministration, and dosage form. The mode of administration can beselected as appropriate for the age and symptoms of the patient. Theeffective dosage of the vaccine is an amount of the vaccine required toalleviate the signs or condition of the disease. The therapeutic effectand toxicity of this vaccine can be determined by standardpharmacological procedures in cell culture or in laboratory animals, forexample, using ED50 (therapeutically effective dose in 50% of thepopulation) or LD50 (lethal dose for 50% of the population). Likewise,the effective dosage of the inducer of anti-Aβ antibody and anti-tauantibody is an amount of the inducer required to induce detectablelevels of anti-Aβ antibody and/or anti-tau antibody in a biologicalsample (including blood, cells, and tissue) collected from the patient.Anti-Aβ antibody and/or anti-tau antibody can be detected by animmunological technique such as ELISA or immunostaining. A skilledartisan would be able to determine an appropriate dosage for the vaccineor the inducer of anti-Aβ antibody and anti-tau antibody.

The route of administration can be selected as appropriate, and examplesof routes of administration include, although not limited to,percutaneous, intranasal, transbronchial, intramuscular,intraperitoneal, intravenous, and subcutaneous routes. Particularlypreferred are intramuscular administration and subcutaneousadministration. Inoculation may be made at a single site or multiplesites.

The dose ratio between therapeutic and toxic effects is a therapeuticindex, and can be expressed as ED50/LD50.

For humans, the vaccine or the inducer of anti-Aβ antibody and anti-tauantibody of the present invention is administered at a single dosage ofabout 1 to 1000 μg, preferably about 10 to 500 μg, and more preferablyabout 50 to 250 μg. The frequency of administration may be once or moreas long as the side effects are within a clinically acceptable range.

In the previous development of vaccines for Alzheimer's disease, studieshave been conducted focusing on antibodies against Aβ and Th2 activity.Thus, it is desirable to measure in advance the antibody titer orcellular immune activity as a vaccine.

For example, the cellular immune activity can be evaluated by separatingand culturing lymphocytes from the body, and measuring their³H-thymidine uptake.

Likewise, the Th2 activity can be evaluated by separating plasma fromperipheral blood, and measuring its antibody titer by ELISA.

Once the vaccine of the present invention is administered to an animalsubject, immune responses against Aβ and/or tau are induced.Specifically, because the above-described amino acid sequence of Aβ1-43,Aβ1-20, Aβ1-40, Aβ1-42, or tau comprises an epitope, antibody productionis induced upon administration of the vaccine of the present invention.

Immune responses against Aβ and tau can be detected by measuring theamount of anti-Aβ antibody and anti-tau antibody produced. The amount ofthe antibodies produced can be measured by a general immunologicaltechnique such as ELISA (enzyme-linked immunosorbent assay). Likewise,the therapeutic effect of the vaccine can be confirmed, for example, asa reduction in the amount of Aβ and tau in brain tissues or as adecrease in Aβ deposition (senile plaques). The amount or the state ofdeposition of Aβ and tau in brain tissues can be observed byimmunohistochemistry and the like.

4. Method for Treating and Preventing Alzheimer's Disease, Method forReducing Brain Aβ and Brain Tau, and Method for Inducing Anti-AβAntibody and Anti-Tau Antibody

The recombinant vector, polypeptide, and vaccine of the presentinvention can be used in a method for treating or preventing Alzheimer'sdisease, a method for reducing brain Aβ and/or brain tau, and a methodfor inducing anti-Aβ antibody and/or anti-tau antibody. Specifically,the present invention provides a method for treating or preventingAlzheimer's disease, a method for reducing brain Aβ and/or brain tau,and a method for inducing anti-Aβ antibody and/or anti-tau antibody,each comprising administering the recombinant vector or polypeptide ofthe present invention to a subject.

In the methods of the present invention, the terms “treating”,“preventing”, and “reducing”, as well as the mode of administration, themethod of formulation, the dosage form, the target (subject) to receivethe administration, the dosage, the route of administration, and thelike are as described in the “3.” section above.

The present invention will be hereinafter described in detail withreference to Examples; however, the invention is not limited to theseExamples.

Example 1

1. Construction of Recombinant Vector (Plasmid) Comprising DNAs EncodingIgL Sequence, Aβ, IgFc Sequence, and Tau

(1) Amplification and Cloning of DNAs Encoding IgL Sequence and IgFcSequence

To clone DNAs encoding an immunoglobulin κ leader (hereinafter “IgL”)sequence and an immunoglobulin Fc (hereinafter “Fc” or “IgFc”) sequence,human peripheral blood-derived mRNA was used as a material to synthesizecDNAs using ReverTra Ace-α- (TOYOBO, Tokyo, Japan). Primers comprisingthe 5′ or 3′ end of the nucleotide sequence encoding each sequence andhaving an appropriate restriction enzyme site (IgL: Bam HI or Xho I;IgFc: Kpn I or Not I) were designed and used to amplify DNAs encoding(or DNAs comprising DNAs encoding) human IgL sequence (SEQ ID NO: 32)and human IgFc sequence using KOD-plus- (Toyobo, Tokyo, Japan). Althoughthe original human IgFc sequence comprises three codons each encoding acysteine residue near the 5′ end, these codons were each modified toencode a serine residue (TGT→TCT or TGC→TCC) during primer design so asto avoid S—S bonding, and the primers thus designed were used to obtainamplification products.

(2) Amplification and Cloning of DNA Encoding Aβ

DNA encoding amyloid-β1-42 (hereinafter “Aβ” or “Aβ1-42”) was preparedby oligonucleotide synthesis, provided that two oligonucleotides werefirst synthesized, which comprised the 5′ or 3′ end of the nucleotidesequence encoding Aβ and were partially complementary to each other (24bp in the middle of the Aβ sequence), because a sequence covering thefull-length (126 bp) was difficult to synthesize. An appropriaterestriction enzyme site (Xho I, Kpn I) was added to each end. Afterthese oligonucleotides were annealed, the entire duplex was prepared bypolymerase reaction.

A construct comprising DNA encoding four repeats of Aβ1-42 sequence(hereinafter also referred to as “Aβ×4”) (SEQ ID NO: 34) was prepared byligating four units of Aβ1-42 via three linker sequences(GGTGGCGGTGGCTCG: SEQ ID NO: 29). First, two constructs, i.e.,“Aβ1-42+linker sequence+Aβ1-6” and “Aβ37-42+linker sequence+Aβ1-42”,were prepared by PCR amplification. Next, both constructs were mixedtogether and used as a template for PCR amplification with a senseprimer designed to have a restriction enzyme site Xho I on the 5′-sideof the nucleotide sequence of Aβ1-42 and an antisense primer designed tohave a restriction enzyme site Kpn I on the 3′-side of Aβ1-42. Theamplification products were electrophoresed on an agarose gel. Amongbands that appeared in a ladder pattern, a band of about 560 bpcorresponding to the molecular weight of Aβ×4 was excised and purified.

(3) Amplification and Cloning of DNA Encoding Tau

DNA encoding tau379-408 (hereinafter “tau” or “tau379-408”) was preparedby preparing a sense strand and an antisense strand by oligonucleotidesynthesis, and annealing the strands to form a duplex.

A construct comprising DNA encoding four repeats of tau sequence(hereinafter “tau×4”) (SEQ ID NO: 23) was prepared by ligating fourunits of tau via three linker sequences (GGTGGCGGTGGCTCG: SEQ ID NO:29). First, two constructs, i.e., “tau379-408+linker sequence+tau1-3”and “tau406-408+linker sequence+tau379-408”, were prepared by PCRamplification. Next, both constructs were mixed together and used as atemplate for PCR amplification with a sense primer designed to have arestriction enzyme site Sal I on the 5′-side of the nucleotide sequenceof tau379-408 and an antisense primer designed to have a stop codon anda restriction enzyme site Not I on the 3′-side of tau379-408. Theamplification products were electrophoresed on an agarose gel. Amongbands that appeared in a ladder pattern, a band of about 420 bpcorresponding to the molecular weight of (tau379-408)×4 was excised andpurified.

Each of the products obtained in (1), (2), and (3) was inserted into acloning vector (Zero Blunt TOPO PCR Kit for Sequencing, Invitrogen,Tokyo, Japan), followed by sequence analysis to select a clone havingthe sequence of interest.

2. Ligation of Four Constructs Comprising DNAs Encoding IgL, Aβ×4, IgFc,and tau×4

Insertion of DNAs Encoding IgL Sequence, Aβ×4, IgFc Sequence, and tau×4into Expression Vector

DNAs encoding the IgL sequence, (Aβ1-42)×4, and the IgFc sequence wereexcised from the cloning vectors at the restriction enzyme sitespreviously added to each DNA, and then purified from an agarose gel(MinElute Gel Extraction Kit, Qiagen, Tokyo, Japan). First, the threeconstructs of IgL, Aβ×4, and IgFc were ligated together using LigationHigh (Toyobo, Tokyo, Japan). To compensate for low ligation efficiencydue to the self-ligation of Aβ×4 and the low yield of the ligationproduct, this ligation product was used as a template for PCRamplification of the IgL-Aβ×4-IgFc ligation sequence, using the samesense primer as that used for the amplification of the IgL sequence(primer comprising the restriction enzyme site BamH I and the 5′ endportion of the IgL sequence) and the same antisense primer as that usedfor the amplification of the IgFc sequence (primer comprising therestriction enzyme site Sal I and the 3′ end portion of the IgFcsequence). Without using the TA cloning site, the pTarget vector wascleaved at the two restriction enzyme sites BamH I and Sal I locatedupstream and downstream, respectively, of the TA cloning site to givethe same overhangs as those of the IgL-Aβ×4-IgFc ligation sequence. TheIgL-Aβ×4-IgFc ligation sequence and the pTarget vector wereelectrophoresed on an agarose gel and purified (MinElute Gel ExtractionKit), and then ligated (Ligation High) to give pTarget/IgL-Aβ×4-IgFc.Sequence analysis confirmed that the proper sequence was obtained.

Next, the two restriction enzyme sites Sal I and Not I immediatelydownstream of the pTarget/IgL-Aβ×4-IgFc insert were cleaved to give thesame overhangs as those of the tau×4 construct. Using Ligation High,tau×4 was integrated to complete the IgL-Aβ×4-IgFc-tau×4 ligationsequence within the pTarget vector (pTarget/IgL-Aβ×4-IgFc-tau×4).

3. Insertion of DNA Encoding IgL-Aβ×4-IgFc-tau×4 into Expression Vector

The IgL-Aβ×4-IgFc-tau×4 ligation sequence was cleaved at the restrictionenzyme sites BamH I at the 5′ end portion and Not I at the 3′ endportion, and excised from the pTarget vector. The pVAX1 vector (LifeTechnologies Japan, Tokyo, Japan) was cleaved at the same BamH I and NotI as those of the insert within the cloning site. TheIgL-Aβ×4-IgFc-tau×4 ligation sequence and the pVAX1 vector were eachelectrophoresed on an agarose gel and then purified, and the resultingproducts were ligated (Ligation High) to complete apVAX1/IgL-Aβ×4-IgFc-tau×4 plasmid. The pVAX1/IgL-Aβ×4-IgFc-tau×4 plasmidwas produced on a large scale in E. coli, and final sequence analysisconfirmed that the proper sequence was obtained.

pVAX1/IgL-Aβ×4-IgFc-tau×4 (hereinafter also referred to as “YM7555”) wasthus obtained as an example recombinant vector comprising DNAs encodingAβ, the IgFc sequence, and tau. The nucleotide sequence of the obtainedpVAX1/IgL-Aβ×4-IgFc-tau×4 insert is shown in SEQ ID NO: 30. The aminoacid sequence of the expression product (polypeptide) (YM7555P) ofIgL-Aβ×4-IgFc-tau×4 is shown in SEQ ID NO: 31. The amino acid sequencesof the IgL sequence, Aβ×4, and tau×4 in YM7555P are shown in SEQ ID NOS:33, 35, and 24, respectively. FIG. 1 shows a schematic diagram of thestructure of IgL-Aβ×4-IgFc-tau×4.

Because the DNA encoding four repeats of Aβ1-42 sequence (denoted as“Aβ×4” or “(Aβ1-42)×4”) and the DNA encoding four repeats of tausequence (denoted as “tau×4” or “(tau379-408)×4”) have highhydrophobicity, and comprise the repeats of sequence, these DNAs have aproblem that they are likely to form a conformation due to self-ligationwhen ligated using a generally known cloning method, and their ligationto a vector or the ligation reaction between the constructs is unlikelyto proceed.

To solve this problem, in the present Examples, the recombinant vectorof the present invention was completed using a combination of thefollowing unique methods developed by the present inventors, i.e., (a)large excess insert method, (b) amplification and ligation method, and(c) 100 colonies method and the like:

(a) Large Excess Insert Method

A general ligation method involves mixing a vector and an insert in aratio of 1:1 to 1:10; in the present Examples, however, the vector andthe insert were mixed in a ratio of 1:10 to 1:1000. For the ligation inthe present Examples, an optimum mixing ratio from ratios of 1:10 to1:1000 was adopted. To prevent self-ligation, the samples were heated at95° C. for 5 minutes immediately before the ligation.

(b) Amplification and Ligation Method

Appropriate restriction enzyme sites were added to both ends of aconstruct, and the construct was simultaneously amplified and ligated byPCR with primers having the 5′ and 3′ terminal nucleotide sequences ofthe final product.

(c) 100 Colonies Method

Because the above-described insert having repeats is susceptible toself-ligation and mutation, 100 colonies of clones were picked up andstored. Then, plasmids were purified from 12-24 colonies, and sequenceduntil clones having the plasmid comprising the proper nucleotidesequence were obtained.

4. Recombinant Peptide and the Like

The Aβ1-42 synthetic peptide was purchased from Peptide Institute, Inc.The expression product (YM3711P) of the recombinant vectorpVAX1/IgL-(Aβ1-42)×4-huIgFc-huIL-4 (YM3711) (WO 2010/110408) and theexpression product (YM7555P) of YM7555 were purified from serum-freeculture supernatants of FreeStyle (trademark) 293-F cells (Invitrogen)transfected with YM3711 and YM7555, respectively. Specifically, theculture supernatants were obtained 4 days after the start of culturingthe cells transfected with each of YM3711 and YM7555, and filtered.Because YM3711P and YM7555P comprised IgFc, these products were furtherpurified using HiTrap Protein G column (GE Healthcare). Eluates werecollected, and confirmed to have strong Aβ immunoreactivity at O.D.280nm with an anti-Aβ monoclonal antibody, 6E10.

The recombinant tau protein was purchased from Wako Pure ChemicalIndustries, Ltd.

5. Confirmation of Protein Expression in Cultured Cells

To confirm whether YM7555 induces the protein of interest, the YM7555plasmid was transfected into HEK293 cells, and the properties of theprotein (YM7555P) secreted into the culture supernatants were analyzedby Western blotting with anti-Aβ antibody or anti-tau antibody. YM7555Pwas also quantitatively analyzed with a commercial sandwich ELISA kitfor Aβ quantification.

The results are shown in FIGS. 2 and 3. Western blotting showed that theexpression product of YM7555 (YM7555P) was detected with both anti-Aβantibody and anti-tau antibody, as expected (FIGS. 2A and 2B). Althoughthe estimated molecular weight of the monomer is about 60 kDa, a majorband of 120 kDa appeared because the expressed YM7555P tends to form adimer to multimer. Because the expression product of YM3711 (YM3711P)(monomer: about 60 kDa) and the (Aβ1-42)×4-IgFc product (Aβ×4-Fc)(monomer: about 40 kDa) detected with the anti-Aβ antibody demonstratedsimilar properties (FIG. 2B), this phenomenon was assumed to be due tothe tendency of the repeated structure to form a complex. The expressionproduct of tau×4-IgFc (tau×4-Fc) (monomer: about 40 kDa) was detectedonly with the anti-tau antibody (FIG. 2A), which confirmed that all thesearched products were detected in an antibody-specific manner.Furthermore, a molecule with a molecular weight smaller than about 60kDa was not detected, which showed that the Aβ1-42 molecule and taumolecule were not separately formed, and an Aβ1-42-tau molecular complexwas expressed as a single molecule and released extracellularly.

Since there is no commercial sandwich ELISA kit that recognizes the tau379-408 sequence, each product was quantified with an ELISA kit for Aβquantification. As a result, sufficient levels of expression wereobserved for all the YM3711P, YM7555P, and Aβ×4-Fc products comprisingthe amino acid sequence of Aβ (FIG. 3). The expression level of YM7555Pwas relatively lower than that of YM3711P, which was extremely high.This phenomenon was assumed to be due to high hydrophobicity of thetranslated tau×4 sequence, which causes a burden on the cells, or makesit difficult for the product to be secreted into the culture supernatantas a soluble protein.

In summary, the experiments showed that the polypeptide comprising bothAβ and tau is expressed as a single molecule from the recombinant vectorof the present invention.

FIG. 8 shows a schematic diagram of the structure of YM7555P.

6. Induction of Anti-Aβ1-42 Antibody and Anti-Tau Antibody in Tg Mice

New Zealand albino rabbits or 3×Tg mice carrying three-types of familialAlzheimer's disease-related mutated genes (B6; 129-Psen1^(tm1Mpm)Tg(APPSwe,tauP301L)1Lfa/Mmjax) were regularly intramuscularly injectedwith YM7555, blood was collected with time, and variations in anti-Aβantibody and anti-tau antibody titers were measured by ELISA. The 3×Tgmice were sacrificed at 2 weeks after the final administration tocollect the brains, and the therapeutic effect according to the presentinvention was evaluated by pathological and immunohistochemical analysisand quantification of proteins in the brain extracts by ELISA.

Initially, the titers of the anti-Aβ antibody and the anti-tau antibodyin the 3×Tg mice were measured.

FIG. 4 shows the schedule of immunization with YM7555 and bloodcollection. Blood was collected from the model mice (Tg) and wild-typemice before the immunization with YM7555 (S0; circles), and the micewere immunized with YM7555 at weeks 0, 2, 4, and 6 (black rhombuses).Blood was collected every 2 weeks after the initial immunization, andantibody titers were measured (white circles; S1, S2, S3, and S4).

The results are shown in FIG. 5. The results of induction of the anti-Aβantibody in the three Tg mice (changes in titer) are each shown in FIGS.5A-C, and the results of induction of the anti-tau antibody in the threeTg mice are each shown in FIGS. 5D-F. For both antibodies, the antibodytiter began to increase at weeks 4 to 8 after the initial immunization,and showed the maximum value at week 12. The OD value increased about10-fold compared to the initial value. In FIG. 5, the symbol ♦ indicatesthe results obtained with 16-fold diluted plasma, and the symbol ▪indicates the results obtained with 32-fold diluted plasma. Thetemporary decrease in antibody titer for the S2 plasma shown in FIG. 5Cis considered to be due to a search error. In FIG. 5, “S0” indicatesblood collection before the immunization, and “S1”, “S2”, “S3”, and “S4”indicate blood collection at weeks 2, 4, 6, and 8, respectively. “S3f”indicates that the blood collection at week 6 is the final bloodcollection.

These results showed that the polypeptide in the form of a singlemolecule expressed from the recombinant vector of the present inventionsimultaneously induces the anti-Aβ antibody and the anti-tau antibody athigh titers in vivo.

In summary, the recombinant vector of the present invention was shown tobe useful as an inducer of the anti-Aβ antibody and the anti-tauantibody.

7. Induction of Anti-Aβ1-42 Antibody and Anti-Tau Antibody in Wild-TypeMice

The similar tests to those in the “6.” section above were conductedusing wild-type mice instead of the Tg mice.

As a result, the level of increase in the antibody titers of the anti-Aβantibody and the anti-tau antibody was comparable to that with the Tgmice.

The results are shown in FIG. 6. The results of induction of the anti-Aβantibody in the three wild-type mice (changes in titer) are each shownin FIGS. 6A-C, and the results of induction of the anti-tau antibody inthe three wild-type mice are each shown in FIGS. 6D-F.

8. Reduction in Aβ Deposition and Tau Deposition in Tg Mice

To confirm whether the recombinant vector of the present inventionreduces Aβ deposition and tau deposition as intended, 3×Tg mice wereregularly administered YM7555, and Aβ and tau in the cerebral cortex(frontal lobe cortex) were quantified by sandwich ELISA. Morespecifically, the 3×Tg mice were sacrificed at 2 weeks after the finaladministration of YM7555, the brains were collected, and each of theproteins, i.e., (A) Aβ (Aβ1-42), (B) total tau (Total tau), and (C)phosphorylated tau (pTau), in the brain extracts was quantified byELISA.

The results are shown in FIG. 7. In FIG. 7, “un Tx” indicates the amountof each protein in Tg mice without the administration of YM7555, and“YM7555 Tx” indicates the amount of each protein in the Tg mice thatreceived the administration of YM7555.

As shown in FIG. 7, the amount of each of the proteins, i.e., (A) Aβ(Aβ1-42), (B) total tau (Total tau), and (C) phosphorylated tau (pTau),was clearly decreased in the YM7555-treated group. In particular,phosphorylated tau (C) having strong neurotoxicity was not detected atall in the YM7555-treated group, which was an unexpected result.

These results showed that the recombinant vector of the presentinvention is useful as a DNA vaccine for reducing brain Aβ and braintau.

The recombinant vector of the present invention was also shown to beextremely useful as a DNA vaccine for the prevention or treatment ofAlzheimer's disease, because it reduced brain Aβ and brain tau, whichare considered to be causative substances for Alzheimer's disease, andin particular, reduced phosphorylated tau with strong toxicity.

SEQUENCE LISTING FREE TEXT

SEQ ID NO: 19: synthetic DNA

SEQ ID NO: 20: synthetic peptide

SEQ ID NO: 21: synthetic DNA

SEQ ID NO: 22: synthetic peptide

SEQ ID NO: 23: synthetic DNA

SEQ ID NO: 24: synthetic peptide

SEQ ID NO: 29: synthetic DNA

SEQ ID NO: 30: synthetic DNA

SEQ ID NO: 31: synthetic peptide

SEQ ID NO: 34: synthetic DNA

SEQ ID NO: 35: synthetic peptide

REFERENCE TO SEQUENCE LISTING SUBMITTED VIA EFS-WEB

This application includes an electronically submitted sequence listingin .txt format. The .txt file contains a sequence listing entitled“2017-11-29_SequenceListing_4456-0239PUS1.txt” created on Nov. 29, 2017and is 61,056 bytes in size. The sequence listing contained in this .txtfile is part of the specification and is hereby incorporated byreference herein in its entirety.

1. A polypeptide comprising a fusion protein having a region consistingof (i)-(vi): (i) four (4) repeats of Aβ1-42 or Aβ1-43 sequence, (ii) animmunoglobulin Fc, and (iii) four (4) repeats of tau sequence, (iv)optionally an Ig leader sequence, (v) optionally peptide linker/s, and(vi) optionally amino acid sequence/s encoded by restriction enzymesite/s, wherein the four (4) repeats of tau sequence comprises four (4)repeats of the amino acid sequences as set forth in SEQ ID NO:
 22. 2.The polypeptide according to claim 1, wherein the amyloid 13 is Aβ1-42.3. The polypeptide according to claim 1, wherein the polypeptide doesnot comprise a portion containing IL-4.
 4. The polypeptide according toclaim 1, wherein the repeats of Aβ1-42 or Aβ1-43, an immunoglobulin Fcsequence, and repeats of tau sequence of the fusion protein arecontained in said order in the fusion protein.
 5. The polypeptideaccording to claim 1, wherein each repeat of Aβ1-42 comprises the aminoacid sequence of SEQ ID NO:
 8. 6. The polypeptide according to claim 1,wherein the four (4) repeats of tau sequence comprises the amino acidsequence as set forth in SEQ ID NO:
 24. 7. A vaccine for prevention ortreatment of Alzheimer's disease, comprising the polypeptide accordingto claim
 1. 8. A vaccine for reducing brain Aβ and brain tau, comprisingthe polypeptide according to claim
 1. 9. An inducer of anti-Aβ antibodyand anti-tau antibody, comprising the polypeptide according claim
 1. 10.A recombinant vector comprising DNA having a region consisting of(i)-(vi): (i) DNA encoding four (4) repeats of Aβ1-42 or Aβ1-43sequence, (ii) DNA encoding an immunoglobulin Fc sequence, (iii) DNAencoding four (4) repeats of tau sequence, (iv) optionally DNA encodingan Ig leader sequence, (v) optionally DNA encoding peptide linker/s, and(vi) optionally restriction enzyme sites, wherein the four (4) repeatsof tau sequence comprises four (4) repeats of the amino acid sequencesas set forth in SEQ ID NO:
 22. 11. A DNA vaccine for prevention ortreatment of Alzheimer's disease, comprising the recombinant vectoraccording to claim
 10. 12. A DNA vaccine for reducing brain Aβ and braintau, comprising the recombinant vector according to claim
 10. 13. Aninducer of anti-Aβ antibody and anti-tau antibody, comprising therecombinant vector according to claim 10.